Stock Ratings | Daiwa Capital raised its price target for AMD to $500; Citizens lowered its price target for KLRS to $25, while maintaining its expectation of a potential upside of 417.6%.
InflaRx N.V. IFRX | 0.00 | |
Orchestra BioMed Holdings, Inc. OBIO | 0.00 | |
Rigel Pharmaceuticals, Inc. RIGL | 0.00 | |
BioAge Labs, Inc. BIOA | 0.00 | |
Kalaris KLRS | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Raymond James: Upgraded InflaRx ( InflaRx N.V.(IFRX.US) ) stock rating to "Strong Buy", raising the price target from $7 to $9.
Barclays: Maintaining an "overweight" rating on Orchestra Orchestra BioMed Holdings, Inc.(OBIO.US) ) stock, while raising the price target from $12 to $13.
Citigroup: Maintaining Rigel Pharmaceuticals' ( Rigel Pharmaceuticals, Inc.(RIGL.US) ) rating at "Buy", while raising the price target from $69 to $81.
BTIG: A preliminary rating of "Buy" for BioAge Labs ( BioAge Labs, Inc.(BIOA.US) ), with a target price of $40.
Citizens: Maintaining Kalaris Therapeutics ( Kalaris Therapeutics, Inc.(KLRS.US) ) rating at "Outperform Market", while lowering the price target from $26 to $25.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| InflaRx N.V.(IFRX.US) | to lift | $9.0 | $2.52 | 257.14% | Raymond James |
| Orchestra BioMed Holdings, Inc.(OBIO.US) | to lift | $13.0 | $4.06 | 220.2% | Barclays |
| Rigel Pharmaceuticals, Inc.(RIGL.US) | to lift | $81.0 | $32.13 | 152.1% | Citigroup |
| Solid Biosciences Inc.(SLDB.US) | to lift | $18.0 | $7.38 | 143.9% | Piper Sandler |
| Legend Biotech(LEGN.US) | to lift | $64.0 | $28.67 | 123.23% | RBC Capital |
| BioAge Labs, Inc.(BIOA.US) | Initial classification | $40.0 | $19.14 | 108.99% | BTIG |
| Kalaris Therapeutics, Inc.(KLRS.US) | cut | $25.0 | $4.83 | 417.6% | Citizens |
| Corbus Pharmaceuticals Holdings Inc(CRBP.US) | cut | $54.0 | $12.15 | 344.44% | Oppenheimer |
| Unicycive Therapeutics(UNCY.US) | cut | $37.0 | $8.51 | 334.78% | Guggenheim |
| PMV Pharmaceuticals, Inc.(PMVP.US) | cut | $5.0 | $1.29 | 287.6% | Oppenheimer |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Canaccord Genuity: Maintaining C3.ai's ( C3.ai Inc(AI.US) ) rating at "Hold", while raising the target price from $7 to $8.
Cantor Fitzgerald: Maintaining a "neutral" rating on ON Semiconductor ( ON Semiconductor Corporation(ON.US) ), while raising the price target from $95 to $100.
Susquehanna: Maintaining a "neutral" rating on Plug Power ( Plug Power Inc.(PLUG.US) ), while raising the price target from $2.75 to $3.75.
Wells Fargo: Maintaining Western Midstream's ( Western Midstream Partners, LP(WES.US) ) rating at "Market-Similar Weight", while raising the price target from $41 to $43.
First Coverage
BTIG: A preliminary rating of "Buy" for BioAge Labs ( BioAge Labs, Inc.(BIOA.US) ), with a target price of $40.
Keefe, Bruyette & Woods: Initial rating for CoinShares ( CoinShares PLC(CSHR.US) ) at "Outperforms Market", with a target price of $9.
Jefferies: Initial rating on Madison Air Solutions ( Madison Air Solutions Corp. Class A(MAIR.US) ) stock at "Hold", with a target price of $45.
Citigroup: Initial rating for NextDecade ( NextDecade Corp.(NEXT.US) ) stock at "Buy", with a target price of $11.
Roth Capital: Initial rating on Unusual Machines ( Unusual Machines(UMAC.US) ) stock at "Buy", with a price target of $25
reduction
Daiwa Capital: Downgraded Advanced Micro Devices Advanced Micro Devices, Inc.(AMD.US) stock to "outperform," while raising its price target from $250 to $500.
Cantor Fitzgerald: Maintaining a "neutral" rating on GitLab GITLAB INC.(GTLB.US) ) stock, while lowering the price target from $30 to $27.
Canaccord Genuity maintains its "Buy" rating on D-Wave Quantum ( D-Wave Quantum(QBTS.US) ), while lowering its price target from $43 to $41.
Wells Fargo: Maintaining an "overweight" rating on VIA Transportation ( Via Transportation, Inc. Class A(VIA.US) ), while lowering the price target from $36 to $30.
DA Davidson: Maintaining a "buy" rating on Western Alliance ( Western Alliance Bancorp(WAL.US) ), while lowering the price target from $93 to $90.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.